These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 35974428)

  • 1. Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study.
    Nasreen S; Febriani Y; Velásquez García HA; Zhang G; Tadrous M; Buchan SA; Righolt CH; Mahmud SM; Janjua NZ; Krajden M; De Serres G; Kwong JC
    Clin Infect Dis; 2023 Feb; 76(4):640-648. PubMed ID: 35974428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
    Skowronski DM; Febriani Y; Ouakki M; Setayeshgar S; El Adam S; Zou M; Talbot D; Prystajecky N; Tyson JR; Gilca R; Brousseau N; Deceuninck G; Galanis E; Fjell CD; Sbihi H; Fortin E; Barkati S; Sauvageau C; Naus M; Patrick DM; Henry B; Hoang LMN; De Wals P; Garenc C; Carignan A; Drolet M; Jassem AN; Sadarangani M; Brisson M; Krajden M; De Serres G
    Clin Infect Dis; 2022 Nov; 75(11):1980-1992. PubMed ID: 35438175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.
    Skowronski DM; Setayeshgar S; Zou M; Prystajecky N; Tyson JR; Sbihi H; Fjell CD; Galanis E; Naus M; Patrick DM; El Adam S; Ahmed MA; Kim S; Henry B; Hoang LMN; Sadarangani M; Jassem AN; Krajden M
    J Infect Dis; 2022 Aug; 226(1):485-496. PubMed ID: 35084500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
    Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
    BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada.
    Skowronski DM; Setayeshgar S; Zou M; Prystajecky N; Tyson JR; Galanis E; Naus M; Patrick DM; Sbihi H; El Adam S; Henry B; Hoang LMN; Sadarangani M; Jassem AN; Krajden M
    Clin Infect Dis; 2022 Apr; 74(7):1158-1165. PubMed ID: 34244723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
    Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada.
    Carazo S; Talbot D; Boulianne N; Brisson M; Gilca R; Deceuninck G; Brousseau N; Drolet M; Ouakki M; Sauvageau C; Barkati S; Fortin É; Carignan A; De Wals P; Skowronski DM; De Serres G
    Clin Infect Dis; 2022 Aug; 75(1):e805-e813. PubMed ID: 34460902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
    Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC;
    Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period.
    Wing S; Thomas D; Balamchi S; Ip J; Naylor K; Dixon SN; McArthur E; Kwong JC; Perl J; Atiquzzaman M; Yeung A; Yau K; Hladunewich MA; Leis JA; Levin A; Blake PG; Oliver MJ
    Clin J Am Soc Nephrol; 2023 Apr; 18(4):491-498. PubMed ID: 36723290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
    Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System.
    Semenzato L; Botton J; Baricault B; Deloumeaux J; Joachim C; Sylvestre E; Dray-Spira R; Weill A; Zureik M
    PLoS One; 2022; 17(9):e0274309. PubMed ID: 36084113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.